Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.02 from other evidence | 0.00 |
| cell type Human Protein Atlas | group enriched outside the brain (hepatocytes) | 0.10 |
| chemistry Open Targets | compounds already reach it: cobicistat, ritonavir, tabimorelin | 1.00 |
| trials ClinicalTrials.gov | 6 Parkinson's trials, 1 stopped | 0.87 |
| literature PubMed | 36 Parkinson's papers of 13,404 | 0.53 |
| pathways Reactome | 7 pathways; mostly iron and oxidative stress | 0.80 |
No case: the score is under the bar. Receipt 8039
Sealed predictions
- CYP3A4 in dopamine neurons, braak+0.58 (p 0.102) → +0.58 (p 0.102)receipt 8046
Swarm cases
receipt 8046: CYP3A4 in dopamine neurons, braak
- power
- full sample +0.54 (p 0.021, n 18), 95% CI +0.10 to +0.80. the interval excludes zero: something may be there, smaller than a half can see.
- confounder
- adjusted for sex: +0.61 (p 0.0072, n 18). holds up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.68 (p 0.0018, n 18). not the mix.
- skeptic
- leave-one-out range +0.48 to +0.65, sign flips 0; without severely affected donors +0.54 (p 0.021, n 18). robust.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for CYP3A4 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts